AGENDA

Fetal Pharmacology & Therapeutics

Workshop sponsored by US FDA and University of Maryland CERSI

Thursday, October 21, 2021

10:00 – 10:05 AM: Welcome and Introduction

Gilbert J. Burckart, Pharm.D. – **Moderator**
Associate Director for Pediatrics, Office of Clinical Pharmacology
Center for Drug Evaluation and Research (CDER)
US Food and Drug Administration (FDA)

10:05 – 10:20 AM: General regulatory considerations

Dionna Green, M.D., FCP
Acting Director, Office of Pediatric Therapeutics (OPT)
Office of the Commissioner (OC), FDA

10:20 – 10:40 AM: Antenatal steroids to prevent respiratory distress syndrome in the preterm newborn – considerations for fetal safety and efficacy

Alan Jobe, M.D., Ph.D.
Cincinnati Children's Hospital
Emeritus Professor of Pediatrics

10:40 – 11:00 AM: Ethical and regulatory considerations

Kevin Prohaska, D.O., MPH
Associate Director/Senior Medical Policy Advisor,
Office of Good Clinical Practice
OC, FDA

Fetal Safety Studies – Moderator: William Slikker, Ph.D., (Center Director, National Center for Toxicological Research (NCTR), FDA)

11:00 – 11:20 AM: Nonclinical assessment to inform maternal and fetal safety in clinical trials enrolling pregnant women

Kim Hatfield, Ph.D.
Lead Toxicologist
Division of Pharmacology Toxicology for Rare Diseases, Pediatric Urology and Reproductive Medicine
CDER, FDA

11:20 – 11:40 AM: Clinical assessment of fetal well-being and fetal safety indicators

Anna David, Ph.D.
Professor of Obstetrics and Maternal Fetal Medicine
Maternal & Fetal Medicine
UCL EGA Institute for Women's Health
Faculty of Population Health Sciences
University College, London, UK

11:40 – 12:00 PM: Model development and effects of opioids on neural tube defects

Amy Inselman, Ph.D.
Research Biologist, Division of Systems Biology
NCTR, FDA

Grace Lee, Ph.D.
Pharmacologist, Division of Pharmacology Toxicology for Neuroscience
CDER, FDA

12:00 – 12:30 PM: LUNCH BREAK

<u>Fetal Therapeutics</u> – Moderator: Gerri Baer, M.D. (Team Leader, Pharmacovigilance & Neonatology Team, OPT, OC, FDA)

12:30 – 12:50 PM: Fetal gene therapy

Simon Waddington, Ph.D.
Professor of Gene Therapy
University College, London
EGA Institute for Women's Health, London, UK

12:50 – 1:10 PM: Fetal arrhythmias

Janette Strasburger, M.D.
Pediatric Cardiology, Pediatrics
Children's Wisconsin
Researcher, Herma Heart Institute
Professor, the Medical College of Wisconsin

1:10 – 1:30 PM: Fetal therapies to target inflammation

Sarah Stock M.D., Ph.D.
Reader and Honorary Consultant Maternal and Fetal Medicine
Usher Institute, University of Edinburgh

1:30 – 1:50 PM: In utero stem cell transplantation for the treatment of prenatally diagnosed diseases

Tippi Mackenzie, M.D.
Professor, Surgery
UCSF Division of Pediatric Surgery and Fetal Treatment Center

Pediatric Surgeon, UCSF Benioff Children's Hospital, San Francisco

1:50 – 2:05 PM: BREAK

2:05 – 3:00 PM: Panel Discussion and Questions

Panel Discussion Moderators:

Dionna Green, M.D., FCP

Jill Morgan, Pharm.D.
Chair, Department of Practice and Science
University of Maryland

Members:

Johannes N. van den Anker, M.D., Ph.D.
Division Chief of Clinical Pharmacology
Children's National Hospital

William Slikker, Ph.D.
Director
NCTR, FDA

Alison Harrill, Ph.D.
Program Officer
NICHD, NIH

Larissa Lapteva, M.D.
Associate Director
OTAT, CBER

Robert Ward, M.D.
Professor Emeritus, Pediatrics
University of Utah

Edress Darsey, Pharm.D.
Global Pediatric Medical Director
Pfizer

Homa K. Ahmadzia, M.D, MPH
Assistant Professor, Division of Maternal-Fetal Medicine
Department of Obstetrics and Gynecology
George Washington University

3:00 – 3:15 PM: Wrap up and Adjourn Day 1
Gilbert J. Burckart, Pharm. D.

Friday, October 22, 2021

10:00 – 10:05 AM: Welcome and Introduction
André Dallmann, Ph.D.
Scientist Systems Pharmacology
Research & Development, Pharmaceuticals,
Bayer AG, Germany

General aspects of maternal-fetal modeling & simulation – Moderator: André Dallmann (Bayer AG)

10:05 – 10:25 AM: Pregnancy-induced anatomical and physiological changes relevant to physiologically-based pharmacokinetic (PBPK) modeling
Anne Zajicek, M.D., Pharm.D., FAAP
Deputy Director, Office of Clinical Research
National Institutes of Health

10:25 – 10:45 AM: Quantifying placental drug transfer with ex vivo cotyledon perfusion assays as PBPK input
Rick Greupink, Pharm.D., Ph.D.
Assistant professor of Pharmacology, member of staff at
Department of Pharmacology & Toxicology
Radboud University Medical Center, Nijmegen, The Netherlands

10:45 – 11:05 AM: Selecting the right dose for pregnant women using PBPK
Ping Zhao, Ph.D.
Senior Program Officer
Bill & Melinda Gates Foundation
Seattle, Washington, United States

Modeling & simulation case studies – Moderator: Johannes N. van den Anker, M.D., Ph.D., Division Chief of Clinical Pharmacology Children's National Hospital)

11:05 – 11:25 AM: Successful prediction of fetal exposure to transported and non-transported drugs using *in vitro* studies and PBPK M&S
Jashvant D. Unadkat, Ph.D.
Milo Gibaldi Endowed Professor, Department of Pharmaceutics
School of Pharmacy, University of Washington

11:25 – 11:45 AM: Mechanistic modeling of placental drug transfer and fetal-neonatal drug exposure

André Dallmann, Ph.D.
Scientist Systems Pharmacology
Research & Development, Pharmaceuticals,
Bayer AG, Germany

11:45 – 12:05 PM: Maternal-fetal PBPK modeling of antipsychotic drugs as case study

Miao Li, Ph.D.
Visiting Scientist
Division of Biochemical Toxicology
NCTR, FDA

12:05 – 12:25 PM: Predicting drug exposure in fetus and genital tract during pregnancy

Adeniyi Olagunju, Ph.D.
Tenure Track Fellow
Centre of Excellence for Long-acting Therapeutics
Department of Pharmacology & Therapeutics
University of Liverpool, Liverpool, UK

Regulatory perspective – Moderator: Dionna Green, M.D., FCP (Acting Director, OPT, OC, FDA)

12:25 – 12:45 PM: MHRA perspective on pregnancy PBPK models

Paola Coppola, M.Sc.
Pharmacokinetics Assessor
Medicines and Healthcare Products, Regulatory Agency
London, UK

12:45 – 1:05 PM: FDA perspective on pregnancy-fetal PBPK models

Leyla Sahin, M.D.
Deputy Director for Safety, Division of Pediatric and Maternal Health, Office of New Drugs, CDER, FDA

1:05 – 1:55 PM: Panel Discussion and Questions

Panel Discussion Moderators:

André Dallmann, Ph.D.

Ping Zhao, Ph.D.

Members:

Khaled Abduljalil, Ph.D
Simcyp Division

Certara, UK

Gilbert J. Burckart, Pharm.D.
Associate Director for Pediatrics, Office of Clinical Pharmacology
CDER
FDA

Jeremiah Momper, Pharm.D., Ph.D.
Associate Professor of Clinical Pharmacy
University of California, San Diego

Zhaoxia Ren, MD, Ph.D
Program Officer at the Obstetric and Pediatric Pharmacology and Therapeutics Branch (OPPTB), NICHD

Stephan Schaller, Ph.D
Principal Consultant, Founder & CEO
esqLABS, Germany

Sander Vinks, Pharm.D, Ph.D, FCP
Director, Division of Clinical Pharmacology
Cincinnati Children's Hospital Medical Center

Xinyuan Zhang, Ph.D
PBPK Co-lead
OCP, CDER, FDA

1:55 – 2:00 PM: Wrap up and Adjourn Day 2
André Dallmann, Ph.D.

Note: all times are in ET